Precise suturing is a key foundation for high-quality reconstruction in minimally invasive surgery. During laparoscopic radical prostatectomy, vesicourethral anastomosis tests the surgeon's ability to control needle-holding angles and needle trajectories, while directly affecting procedural stability and reproducibility. In this interview, Oncology Frontier – UroStream invited Professor Zhenghua Ju of Fujian Cancer Hospital to discuss the technical challenges of laparoscopic vesicourethral anastomosis, the evolution of the 360° suturing theory into the “Three Fundamental Principles of Surgical Suturing,” and the clinical value of standardized dissemination and training.

The 2026 Pujiang Prostate Cancer Academic Conference was successfully held in Shanghai under the central theme of “Standardization, Precision Breakthroughs, Chinese Innovation, and Global Collaboration.” The conference aimed to promote the standardized diagnosis and treatment of prostate cancer in China while advancing key technological innovations. Following the meeting, Oncology Frontier – UroStream invited Professor Hongkai Wang of Fudan University Shanghai Cancer Center to discuss recent innovations in robotic radical prostatectomy, balancing oncological control with functional preservation, and the development of domestically developed surgical robots.

Treatment decisions for advanced renal cell carcinoma (RCC) are shifting from traditional clinical risk stratification toward precision classification based on molecular characteristics. What is the scientific rationale behind this trend? Which key molecular biomarkers hold the greatest promise for guiding treatment selection and sequencing? And what are the major obstacles to translating scientific discoveries in precision medicine into clinical practice?

Approximately 101,000 new cases of bladder cancer are diagnosed annually in China, making it the 11th most common malignancy. The disease is more prevalent in southern China than in the north, and its incidence is trending toward younger age groups. Meanwhile, high-risk localized or locally advanced prostate cancer carries a substantial risk of biochemical recurrence and distant metastasis, and local treatment alone is often insufficient to address the full spectrum of clinical needs.

The “Gaobo Medical Forum—6th Shanghai Clinical Application Seminar on Hematopoietic Stem Cell Transplantation and Training Course on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation,” hosted by the National Clinical Research Center for Hematologic Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Shanghai Zhaxin Hospital/Gaobo Medical Group and Shanghai Liquan Hospital, was held in Shanghai on August 29–30, 2026. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Dehui Zou of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss optimization and alternative strategies for conditioning regimens in autologous hematopoietic stem cell transplantation (ASCT) for lymphoma. Against the backdrop of increasingly diverse novel therapies, Professor Zou explored the precise positioning and clinical value of ASCT, as well as the integration of innovative therapies such as CAR-T with conventional transplantation, and shared insights into future directions.